Loading…
← CockpitCompetitor Analysis › TKNO Alpha Teknova, Inc.Open in the cockpit ↗

Alpha Teknova, Inc.TKNOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 97
Mkt cap
$496M
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$4.22M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-26.0 pp
WACC 9.7%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$7.88
1D+3.0%
1W-8.6%
1M+6.6%
3M+12.6%
6M+113.0%
YTD+107.4%
1Y+84.1%
ATR %8.0%
Beta1.08
52w lowhigh16.9% off high

What Alpha Teknova does

Employees: 158

Alpha Teknova at a glance

Size Alpha Teknova (TKNO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $496M, the 2676th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.88 on 18 Nov 2026.

Performance Over six months the shares gained 113.0%, against -18.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 15.4% over the last twelve months (peer median +9.8%); the operating margin is -31.6% (peer median 10.9%).

Valuation It trades at 11.0× enterprise value to sales against a peer median of 3.7× (5th most expensive of 20).

Capital Return on invested capital runs 26.0 points below its cost of capital (9.7% WACC).

Short interest Short interest is 2.5% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 2026TKNO 204Peer median 83
Six months, rebased to 100: Alpha Teknova against the median of its 20 peers (local-currency closes).

Alpha Teknova financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$46.0M$40.5M$37.7M$36.7M$41.4M
Revenue growth—+7%+3%-11%—
Gross profit$15.6M$12.3M$6.08M$9.15M$16.3M
EBITDA-$8.18M-$9.63M-$18.3M-$24.8M-$25.4M
Net income-$16.0M-$17.3M-$26.7M-$36.8M-$47.5M
Free cash flow-$6.38M-$9.89M-$13.5M-$26.8M-$55.5M
Capital expenditure$814,000$1.15M$1.12M$7.93M$28.1M
Total debt$27.0M$28.3M$30.2M$30.5M$42.3M

Quarterly statements and history in the cockpit →

Alpha Teknova competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%600513003090600222AARTIDRUGS0021071666GYRE603207301277GUJTHEMINDPEGTXRGNXHNSA600624SMSPHARMATKNO6-month return →1-month return →
Up and to the right = strong over both horizons. Alpha Teknova is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×25×50×75×600513003090600222AARTIDRUGS0021071666603207300584GUJTHEMEGTX688373HNSA600624TKNORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alpha Teknova is the large dot.

Alpha Teknova competitors and peer comparison

How Alpha Teknova compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alpha Teknova against its 20 peers (data as of 18 Nov 2026)
MeasureTKNOPeer medianRank in peer set
1-month return+6.6%-2.1%7th highest of 21
6-month return+113.0%-18.4%2nd highest of 21
Distance from 52-week high-16.9%-35.5%5th highest of 21
Revenue growth (TTM)+15.4%+9.8%6th highest of 20
Operating margin-31.6%10.9%6th lowest of 20
EV / Sales11.0×3.7×5th most expensive of 20
ROIC minus cost of capital-26.0 pp-2.4 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a

Questions

Which companies are Alpha Teknova's closest peers?
The cockpit's peer set: Jiangsu Lianhuan Pharmaceutical (600513.SS), Daewoong (003090.KS), Henan Taloph Pharmaceutical Stock (600222.SS), Aarti Drugs (AARTIDRUGS.NS), Shandong Wohua Pharmaceutical (002107.SZ), Tong Ren Tang Technologies (1666.HK), Gyre Therapeutics (GYRE), Shanghai Xiao Fang Pharmaceutical (603207.SS).
Is Alpha Teknova expensive compared with its peers?
On ev / sales it trades at 11.0× against a peer median of 3.7×, 5th most expensive of 20 in its peer set.
How has Alpha Teknova stock performed?
Over six months to 18 Nov 2026 the shares returned +113.0% against -18.4% for the median peer; over one year +84.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.